ES2770705T3 - Terapias de antibióticos peptídicos derivados del búfalo de agua - Google Patents
Terapias de antibióticos peptídicos derivados del búfalo de agua Download PDFInfo
- Publication number
- ES2770705T3 ES2770705T3 ES15829088T ES15829088T ES2770705T3 ES 2770705 T3 ES2770705 T3 ES 2770705T3 ES 15829088 T ES15829088 T ES 15829088T ES 15829088 T ES15829088 T ES 15829088T ES 2770705 T3 ES2770705 T3 ES 2770705T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- tim
- ile
- trp
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000030939 Bubalus bubalis Species 0.000 title description 3
- 239000003910 polypeptide antibiotic agent Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 49
- 150000002500 ions Chemical class 0.000 claims description 26
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 13
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 241000543381 Cliftonia monophylla Species 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 241000233866 Fungi Species 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 7
- 239000003242 anti bacterial agent Substances 0.000 abstract 2
- 230000003115 biocidal effect Effects 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 38
- 239000002253 acid Substances 0.000 description 17
- 239000004599 antimicrobial Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000011148 porous material Substances 0.000 description 9
- 230000000845 anti-microbial effect Effects 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 6
- JFUIHGAGFMFNRD-UHFFFAOYSA-N fica Chemical compound FC1=CC=C2NC(C(=O)NCCS)=CC2=C1 JFUIHGAGFMFNRD-UHFFFAOYSA-N 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 241001182492 Nes Species 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 101100285518 Drosophila melanogaster how gene Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 101100346656 Drosophila melanogaster strat gene Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000392000 Licina Species 0.000 description 2
- 241000219823 Medicago Species 0.000 description 2
- 241001378740 Mugil liza Species 0.000 description 2
- 241000275031 Nica Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 241000252084 Anguilla Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241001622618 Borbo Species 0.000 description 1
- 241000288950 Callithrix jacchus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- 241001135265 Cronobacter sakazakii Species 0.000 description 1
- 241000205706 Cystoisospora felis Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000936969 Fusobacterium equinum Species 0.000 description 1
- 101000973623 Homo sapiens Neuronal growth regulator 1 Proteins 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 101150048797 LIPH gene Proteins 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 241001446467 Mama Species 0.000 description 1
- 241000108056 Monas Species 0.000 description 1
- 101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
- 101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
- 241001468278 Mycoplasma felis Species 0.000 description 1
- 241000579205 Mycoplasma suis Species 0.000 description 1
- 235000012093 Myrtus ugni Nutrition 0.000 description 1
- 101150096752 NCAM1 gene Proteins 0.000 description 1
- 101150005851 NOS gene Proteins 0.000 description 1
- 241001538234 Nala Species 0.000 description 1
- 102100022223 Neuronal growth regulator 1 Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical compound ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 description 1
- 241001442654 Percnon planissimum Species 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 244000118351 Pluchea indica Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000180027 Pseudomonas cedrina Species 0.000 description 1
- 241000589538 Pseudomonas fragi Species 0.000 description 1
- 241001277679 Pseudomonas mandelii Species 0.000 description 1
- 241001074440 Pseudomonas mediterranea Species 0.000 description 1
- 241000218902 Pseudomonas synxantha Species 0.000 description 1
- 238000004617 QSAR study Methods 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000201871 Staphylococcus felis Species 0.000 description 1
- 241000194048 Streptococcus equi Species 0.000 description 1
- 241000194021 Streptococcus suis Species 0.000 description 1
- 241000194054 Streptococcus uberis Species 0.000 description 1
- 244000061461 Tema Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001038 ionspray mass spectrometry Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- LKACJLUUJRMGFK-UHFFFAOYSA-N methylsulfonal Chemical compound CCS(=O)(=O)C(C)(CC)S(=O)(=O)CC LKACJLUUJRMGFK-UHFFFAOYSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- SYDXFYIGIIAPLB-OKRPGNDBSA-N ntii Chemical compound Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC(=C3NC=25)N=C=S)O)CC1)O)CC1CC1 SYDXFYIGIIAPLB-OKRPGNDBSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940099990 ogen Drugs 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N37/46—N-acyl derivatives
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
- A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
- A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
- A01N47/44—Guanidine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/50—Isolated enzymes; Isolated proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462032737P | 2014-08-04 | 2014-08-04 | |
| US14/483,083 US9029319B1 (en) | 2014-08-04 | 2014-09-10 | Water buffalo derived peptide antibiotic therapies |
| US14/678,558 US9273097B2 (en) | 2014-08-04 | 2015-04-03 | Water buffalo derived peptide antibiotic therapies |
| US14/692,518 US9163064B1 (en) | 2014-08-04 | 2015-04-21 | Water buffalo derived monomeric peptides containing proline for antibiotic therapies |
| US14/750,709 US9701716B2 (en) | 2014-08-04 | 2015-06-25 | Water buffalo derived dimeric peptide containing proline for antibiotic therapies |
| PCT/US2015/042435 WO2016022335A1 (en) | 2014-08-04 | 2015-07-28 | Water buffalo derived peptide antibiotic therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2770705T3 true ES2770705T3 (es) | 2020-07-02 |
Family
ID=53038201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15829088T Active ES2770705T3 (es) | 2014-08-04 | 2015-07-28 | Terapias de antibióticos peptídicos derivados del búfalo de agua |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9029319B1 (enExample) |
| EP (1) | EP3179855B1 (enExample) |
| JP (1) | JP6802148B2 (enExample) |
| CN (1) | CN108064131A (enExample) |
| AR (1) | AR101416A1 (enExample) |
| AU (1) | AU2015298629B2 (enExample) |
| BR (1) | BR112017002166B1 (enExample) |
| CA (1) | CA2956778C (enExample) |
| CY (1) | CY1122747T1 (enExample) |
| DK (1) | DK3179855T3 (enExample) |
| ES (1) | ES2770705T3 (enExample) |
| HR (1) | HRP20200195T1 (enExample) |
| HU (1) | HUE048461T2 (enExample) |
| LT (1) | LT3179855T (enExample) |
| MX (1) | MX373912B (enExample) |
| PL (1) | PL3179855T3 (enExample) |
| PT (1) | PT3179855T (enExample) |
| RS (1) | RS59987B1 (enExample) |
| SI (1) | SI3179855T1 (enExample) |
| SM (1) | SMT202000100T1 (enExample) |
| WO (1) | WO2016022335A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9029319B1 (en) | 2014-08-04 | 2015-05-12 | Centaur, Inc. | Water buffalo derived peptide antibiotic therapies |
| CN109553677B (zh) * | 2018-11-30 | 2021-12-14 | 东北农业大学 | 基于两栖类蛙源抗菌肽的衍生肽w8及其制备方法和应用 |
| JP2023519844A (ja) * | 2020-03-30 | 2023-05-15 | エニジェン カンパニー リミテッド | 新規の抗細菌性ペプチド及びその使用 |
| CN113831395B (zh) | 2021-11-26 | 2022-02-22 | 中国海洋大学 | 一种重组抗菌肽TrSub、制备方法及其应用 |
| CN114752533B (zh) * | 2022-05-05 | 2026-07-17 | 北京市科学技术研究院资源环境研究所 | 一种用于重油污染的生物修复制剂及其应用 |
| CN119220434B (zh) * | 2024-09-25 | 2025-05-30 | 青岛农业大学 | 一种具有高载硒活性的丁酸梭菌的菌制剂后生元及其应用 |
| CN120842027B (zh) * | 2025-08-12 | 2026-04-24 | 山东植知源生态工程有限公司 | 一种含大豆磷脂和羽毛粉的生物有机肥及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003520808A (ja) * | 2000-01-21 | 2003-07-08 | ザ バーナム インスティチュート | プロアポトーシス活性を有するキメラ前立腺ホーミングペプチド |
| US8202835B2 (en) | 2005-06-17 | 2012-06-19 | Yitzchak Hillman | Disease treatment via antimicrobial peptides or their inhibitors |
| DE102009007381A1 (de) * | 2009-01-29 | 2010-08-05 | Amp-Therapeutics Gmbh & Co. Kg | Antibiotische Peptide |
| ES2761835T3 (es) * | 2009-02-06 | 2020-05-21 | Technophage Investig E Desenvolvimento Em Biotecnologia Sa | Fagos antibacterianos, péptidos de fagos y métodos de uso de los mismos |
| US9029319B1 (en) | 2014-08-04 | 2015-05-12 | Centaur, Inc. | Water buffalo derived peptide antibiotic therapies |
-
2014
- 2014-09-10 US US14/483,083 patent/US9029319B1/en active Active
-
2015
- 2015-04-03 US US14/678,558 patent/US9273097B2/en active Active
- 2015-04-21 US US14/692,518 patent/US9163064B1/en active Active
- 2015-06-25 US US14/750,709 patent/US9701716B2/en active Active
- 2015-07-27 SM SM20200100T patent/SMT202000100T1/it unknown
- 2015-07-28 AU AU2015298629A patent/AU2015298629B2/en active Active
- 2015-07-28 JP JP2017506818A patent/JP6802148B2/ja active Active
- 2015-07-28 EP EP15829088.2A patent/EP3179855B1/en active Active
- 2015-07-28 WO PCT/US2015/042435 patent/WO2016022335A1/en not_active Ceased
- 2015-07-28 MX MX2017001566A patent/MX373912B/es active IP Right Grant
- 2015-07-28 DK DK15829088.2T patent/DK3179855T3/da active
- 2015-07-28 BR BR112017002166-8A patent/BR112017002166B1/pt active IP Right Grant
- 2015-07-28 SI SI201531086T patent/SI3179855T1/sl unknown
- 2015-07-28 LT LTEP15829088.2T patent/LT3179855T/lt unknown
- 2015-07-28 ES ES15829088T patent/ES2770705T3/es active Active
- 2015-07-28 HR HRP20200195TT patent/HRP20200195T1/hr unknown
- 2015-07-28 HU HUE15829088A patent/HUE048461T2/hu unknown
- 2015-07-28 CN CN201580052880.XA patent/CN108064131A/zh active Pending
- 2015-07-28 CA CA2956778A patent/CA2956778C/en active Active
- 2015-07-28 PT PT158290882T patent/PT3179855T/pt unknown
- 2015-07-28 RS RS20200124A patent/RS59987B1/sr unknown
- 2015-07-28 PL PL15829088T patent/PL3179855T3/pl unknown
- 2015-08-04 AR ARP150102491A patent/AR101416A1/es not_active Application Discontinuation
-
2020
- 2020-02-07 CY CY20201100121T patent/CY1122747T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE048461T2 (hu) | 2020-07-28 |
| RS59987B1 (sr) | 2020-03-31 |
| US9029319B1 (en) | 2015-05-12 |
| EP3179855A4 (en) | 2018-05-23 |
| US9163064B1 (en) | 2015-10-20 |
| SMT202000100T1 (it) | 2020-03-13 |
| WO2016022335A1 (en) | 2016-02-11 |
| DK3179855T3 (da) | 2020-02-17 |
| CA2956778C (en) | 2021-10-26 |
| AU2015298629A1 (en) | 2017-02-16 |
| US9701716B2 (en) | 2017-07-11 |
| HRP20200195T1 (hr) | 2020-08-07 |
| BR112017002166B1 (pt) | 2022-08-16 |
| PL3179855T3 (pl) | 2020-06-29 |
| CN108064131A (zh) | 2018-05-22 |
| US20160031940A1 (en) | 2016-02-04 |
| CY1122747T1 (el) | 2021-03-12 |
| PT3179855T (pt) | 2020-02-21 |
| JP6802148B2 (ja) | 2020-12-16 |
| NZ728651A (en) | 2021-11-26 |
| EP3179855B1 (en) | 2019-11-20 |
| US20160031954A1 (en) | 2016-02-04 |
| SI3179855T1 (sl) | 2020-04-30 |
| BR112017002166A2 (pt) | 2018-01-16 |
| MX2017001566A (es) | 2017-10-12 |
| CA2956778A1 (en) | 2016-02-11 |
| LT3179855T (lt) | 2020-02-25 |
| JP2017533177A (ja) | 2017-11-09 |
| AR101416A1 (es) | 2016-12-14 |
| EP3179855A1 (en) | 2017-06-21 |
| US9273097B2 (en) | 2016-03-01 |
| MX373912B (es) | 2020-07-10 |
| AU2015298629B2 (en) | 2019-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0750506A4 (en) | ANTIMICROBIAL PREPARATIONS WITH A WIDE RANGE AND METHOD FOR THEIR USE | |
| ATE456959T1 (de) | Stabilisierte tumorantigen-mrna mit erhöhtem g/c- gehalt | |
| RU2020111236A (ru) | Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности | |
| EA200900272A1 (ru) | Комбинации для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом | |
| RU2017101705A (ru) | Фармацевтическая композиция, предназначенная для применения для предупреждения и/или лечения заболевания, которое развивается или прогрессирует вследствие снижения или утраты активности фактора свертывания крови viii и/или активированного фактора свертывания крови viii | |
| EP3903823A2 (en) | Antimicrobial peptides and methods of use thereof | |
| WO2004076644A3 (en) | A composition for delivering an agent to a target cell and uses thereof | |
| WO2011149964A3 (en) | Methods for treating or preventing vascular graft failure | |
| CO5580776A2 (es) | Formulacion farmaceutica estable en solucion de oxaliplatino | |
| WO2011107653A3 (en) | Use of levodopa, carbidopa and entacapone for treating parkinson's disease | |
| NZ603028A (en) | Tfpi inhibitors and methods of use | |
| PH12019502522A1 (en) | Oncolytic virus and method | |
| WO2008108910A3 (en) | Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy | |
| EP1579001A4 (en) | MATERIAL AND METHOD FOR PREVENTING AND TREATING RNA VIRUS DISEASES | |
| BR112022019846A2 (pt) | Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostos | |
| RU2013126888A (ru) | ИММУНОМОДУЛИРУЮЩИЕ КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ, СОДЕРЖАЩИЕ ИММУНОГЕННЫЕ ФРАГМЕНТЫ АроВ100 | |
| HK1216007A1 (zh) | 人体生长激素和白蛋白的融合、制剂及其用途 | |
| BRPI0408500A (pt) | tratamento do diabetes do tipo 1 com inibidores de pde5 | |
| Biggar et al. | Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: a German-Austrian, single-arm, open-label, prospective, noninterventional, observational study | |
| MX2011004176A (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo. | |
| CN112040968B (zh) | 对人肌肉烟碱性乙酰胆碱受体具有高结合亲和力的生物活性肽 | |
| WO2005007118A3 (en) | Treatment or prevention of damage due to radiation exposure | |
| KR20240042416A (ko) | 암의 치료 및/또는 예방을 위한 의약품 | |
| WO2019196965A3 (en) | Pharmacy preparation for malignant melanoma treatment | |
| WO2006119402A3 (en) | C-linked glucoronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth |